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Experimental autoimmune encephalomyelitis 
(EAE) has been used as a model for multiple 
sclerosis (MS) for over four decades. Our un-
derstanding of EAE and the immune cells that 
mediate the pathology of the disease has grown 
tremendously during this time. However, as the 
field of immunology evolves, many of the fun-
damental observations in EAE are questioned 
and revisited to further our understanding of 
EAE and ultimately enhance our understand-
ing of MS. Although EAE was initially induced 
by immunization with myelin proteins emulsi-
fied in CFA, it can also be induced by adoptive 
transfer of myelin-specific CD4+ Th1 cells into   
naive recipient mice (McDonald and Swanborg,   
1988; Ando et al., 1989; Waldburger et al., 1996; 
Yura et al., 2001; Lovett-Racke et al., 2004; 
Gocke et al., 2007). The observation that my-
elin-specific CD4+ Th1 cells were sufficient to 
induce EAE focused MS research on these IFN-– 
producing T cells in MS patients. Although 
myelin-specific T cells were found in both MS 
patients and healthy individuals, which raised 
questions as to the relevance of these cells in 
MS patients, it does appear that myelin-spe-
cific T cells from MS patients are more likely 
to have a Th1 phenotype (Olsson et al., 1990; 
Sun et al., 1991; Voskuhl et al., 1993; Pelfrey 
et al., 2000). Subsequently, several studies dem-
onstrated that although healthy individuals had   
myelin-specific T cells, these cells were naive, 
whereas MS patients had activated and mem-
ory myelin-specific T cells, indicating that these   
cells had been previously activated (Allegretta 
et al., 1990; Lovett-Racke et al., 1998; Burns 
et al., 1999). In addition, a clinical trial with an 
altered peptide ligand from myelin basic protein 
(MBP), which was intended to down-regulate 
myelin-specific T cells, actually exacerbated 
disease in several MS patients, which was asso-
ciated with increased frequency of MBP-specific 
T cells that produced IFN-, suggesting that 
MS is mediated by myelin-specific Th1 cells 
(Bielekova et al., 2000).
As a result, several studies focused on IFN- 
as the pathogenic molecule in EAE and MS. 
Surprisingly, IFN-–deficient mice and mice 
given antibodies to neutralize IFN- were still 
susceptible to EAE (Lublin et al., 1993; Ferber 
et al., 1996; Heremans et al., 1996; Willenborg 
et al., 1996). The number of myelin-specific 
CD4+ T cells was expanded in these mice, 
CORRESPONDENCE  
Amy E. Lovett-Racke:  
lovett-racke.1@osu.edu
Abbreviations used: CNS, cen-
tral nervous system; EAE, ex-
perimental autoimmune 
encephalomyelitis; MBP, my-
elin basic protein; MS, multiple 
sclerosis; NS, nonsense.
T-bet is essential for encephalitogenicity  
of both Th1 and Th17 cells
Yuhong Yang,1 Jeffrey Weiner,1 Yue Liu,1,2 Alan J. Smith,2 David J. Huss,2 
Ryan Winger,1 Haiyan Peng,1 Petra D. Cravens,3 Michael K. Racke,1  
and Amy E. Lovett-Racke2
1Department of Neurology and 2Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University 
Medical Center, Columbus, OH 43210
3Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75390
The extent to which myelin-specific Th1 and Th17 cells contribute to the pathogenesis of 
experimental autoimmune encephalomyelitis (EAE) is controversial. Combinations of inter-
leukin (IL)-1, IL-6, and IL-23 with transforming growth factor  were used to differenti-
ate myelin-specific T cell receptor transgenic T cells into Th17 cells, none of which could 
induce EAE, whereas Th1 cells consistently transferred disease. However, IL-6 was found to 
promote the differentiation of encephalitogenic Th17 cells. Further analysis of myelin-
specific T cells that were encephalitogenic in spontaneous EAE and actively induced EAE 
demonstrated that T-bet expression was critical for pathogenicity, regardless of cytokine 
expression by the encephalitogenic T cells. These data suggest that encephalitogenicity of 
myelin-specific T cells appears to be mediated by a pathway dependent on T-bet and not 
necessarily pathway-specific end products, such as interferon  and IL-17.
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tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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EAE, often with atypical clinical signs, when transferred into 
recipient mice (Langrish et al., 2005; McGeachy et al., 2007; 
Stromnes et al., 2008). However, it has not been shown 
whether myelin-specific Th17 cells generated in vitro with 
IL-6 + TGF- can induce EAE. Naive TCR transgenic sple-
nocytes from a mouse that expresses TCR genes V2.3/
V8.2 that recognize MBP Ac1-11 were differentiated in vi-
tro with peptide plus IL-6 + TGF- or IL-12. Flow cyto-
metric analysis was used to determine the percentage of CD4+ 
T  cells  producing  IFN-  and  IL-17  under  Th1-inducing   
(IL-12) and Th17-inducing (IL-6 + TGF-) conditions. Dif-
ferentiation of TCR transgenic T cells with IL-12 resulted in 
13%  of  CD4+  T  cells  expressing  IFN-,  and  >40%  of 
CD4+ T cells differentiated with IL-6 + TGF- expressed 
IL-17 (Fig. 1 A). To determine if the Th17 cells generated by 
IL-6 + TGF- were encephalitogenic, Th17 and Th1 cells 
generated in vitro were transferred into naive B10.PL recipi-
ents. Although all of the mice that received Th1 cells devel-
oped EAE, as previously observed (Gocke et al., 2007), none 
of the mice that received the Th17 cells developed disease 
(Fig. 1 B). In addition, no CNS-infiltrating mononuclear 
cells were recovered from the mice receiving the Th17 cells. 
Pure populations of naive TCR transgenic T cells acquired 
by cell sorting of CD4+ CD62L+ cells were also differentiated 
in vitro with IL-6 + TGF-, but these cells also failed to 
transfer EAE to recipient mice (unpublished data). It was possi-
ble that the Th17 cells were pathogenic but unable to access 
the CNS in the absence of Th1 cells. However, cotransfer of 
myelin-specific Th17 cells with suboptimal numbers of my-
elin-specific Th1 cells failed to induce EAE (Table I). Al-
though pertussis toxin is not necessary to transfer EAE with 
the TCR transgenic Th1 cells, perhaps pertussis toxin was 
necessary for trafficking of Th17 cells to the CNS. However, 
i.p. injection of pertussis toxin on days 0 and 2 with transfer 
of Th17 cells also failed to induce EAE (Table I).
Th17 cells differentiated with IL-6 + TGF- do not have  
a stable phenotype
Because IL-6 + TGF- were capable of differentiating the 
TCR transgenic T cells into Th17 cells but failed to generate 
encephalitogenic T cells, we investigated the possibility that 
IL-23 was critical in the differentiation of pathogenic Th17 
cells, because IL-23 had been shown to enhance the expan-
sion  of  myelin-specific  Th17  cells  from  immunized  mice 
(Langrish et al., 2005). It was also possible that primary dif-
ferentiation was not sufficient to generate highly encephalito-
genic Th17 cells and that restimulation with antigen may be 
required. Therefore, TCR transgenic T cells were differenti-
ated with MBP Ac1-11 in the presence of IL-6 + TGF- in 
the presence or absence of IL-23. These cells were transferred 
into naive B10.PL mice and only one mouse in the IL-6 + 
TGF- + IL-23 group developed EAE (Table I). After the 
primary differentiation in vitro, the Th17 cells were rested, 
restimulated with MBP Ac1-11, and transferred into recipi-
ent mice. All of the mice developed an early onset, severe 
EAE (Table I). However, analysis of the cytokine profile of 
which may have occurred because of the loss of regulatory 
cells that were dependent on IFN- (Chu et al., 2000). How-
ever, several studies that specifically suppressed IFN- in the 
myelin-specific T cells before transfer into recipient mice 
demonstrated that altering the signaling pathway that results 
in IFN- production in CD4+ T cells decreases the encepha-
litogenic capacity of these cells (Racke et al., 1994; Racke   
et al., 1995; Lovett-Racke et al., 2004). In addition, STAT4 
and T-bet, transcription factors in the Th1 cell differentiation 
pathway, have been shown to be critical for EAE induction 
(Chitnis et al., 2001; Bettelli et al., 2004; Lovett-Racke et al., 
2004; Nath et al., 2006). Together, these data suggest that the 
differentiation pathway that generates Th1 cells may be im-
portant in encephalitogenicity, but the downstream produc-
tion of IFN- by myelin-specific T cells may not be critical.
More recently, a new phenotype of CD4+ T cells was de-
scribed in EAE that appears to be pathogenic. Stimulation   
of myelin-specific T cells from myelin-immunized mice with 
IL-23 promotes the expansion of T cells that express IL-17 
(Langrish et al., 2005). Transfer of these myelin-specific IL-17–
producing T cells, called Th17 cells, into naive mice induced 
EAE. In addition, microarray analysis of MS tissues indicates 
that IL-17 is present in MS lesions (Lock et al., 2002). We and 
others have shown that Th17 cells are found in the central 
nervous system (CNS) of mice after adoptive transfer of my-
elin-specific Th1 cells; however, the Th17 cells are derived 
from the recipient and not the transferred Th1 cells (Gocke   
et al., 2007; Lees et al., 2008). In addition, IL-17–deficient 
mice developed EAE, although disease severity is reduced and 
disease course altered (Komiyama et al., 2006; Haak et al., 
2009). These studies have raised the question as to whether the 
pathogenic T cells in EAE and MS are actually Th1 or Th17 
cells, or whether both populations contribute to the disease.
Several studies have defined cytokines, primarily IL-6 and 
TGF-, which can induce the differentiation of CD4+ T 
cells into Th17 cells in vitro (Bettelli et al., 2006; Mangan   
et al., 2006; Veldhoen et al., 2006). However, it has not been 
demonstrated whether pure populations of myelin-specific 
Th17 cells can induce EAE, because previous studies have 
used  lymphocytes  from  immunized  mice  that  have  been 
skewed in vitro to enhance either IFN- or IL-17 expres-
sion, but not exclude the other population (McGeachy et al., 
2007; Stromnes et al., 2008). In the present study, we use 
TCR transgenic T cells specific for MBP Ac1-11 to study the 
differentiation of Th17 cells and their ability to induce EAE. 
In addition, we characterized the pathogenic autoreactive   
T cells in both induced and spontaneous EAE.
RESULTS
IL-6 + TGF- fail to generate encephalitogenic Th17 cells
Several recent studies have defined cytokines that induce the 
differentiation of Th17 cells (Bettelli et al., 2006; Mangan   
et al., 2006; Veldhoen et al., 2006). It has also been demon-
strated that myelin-specific T cells from immunized mice can 
be restimulated with IL-23 to enhance IL-17 production. 
These  IL-23–driven  IL-17–producing  T  cells  can  induce JEM VOL. 206, July 6, 2009 
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cells (6.6%), and a population that expressed both IFN- and 
IL-17 (5.7%; Fig. 1 C). Thus, restimulation of the Th17 cells 
with antigen induced IFN- production, making it unclear 
whether the IL-17– or IFN-–producing cells caused the 
disease. This also suggests that Th17 cells may not have a stable 
phenotype, which was also observed with the OVA-specific 
OT-II TCR transgenic T cells (Lee et al., 2009). Therefore, 
the CNS-infiltrating cells, gated on CD45 and V8 (expressed 
by the TCR transgenic T cells), were analyzed by flow cy-
tometry. Although three populations of V8+ T cells were 
identified in the CNS as defined by cytokine production, 
the majority (54% single positive and 13% double positive) of 
CNS-infiltrating T cells produced IFN- (Fig. 1 C), suggest-
ing that the severe disease was associated with an expansion of 
V8+ IFN-+–producing cells in the CNS. In an effort to 
maintain the Th17 phenotype upon restimulation with anti-
gen, IL-23 or IL-1 were added during the restimulation 
with antigen, yet the cells still produced both IFN- and 
IL-17 and transferred disease similar to the cells restimulated 
with antigen only (Table I).
Role of IL-1 and IL-23 in the differentiation of Th17 cells
Because IL-6 + TGF- were capable of differentiating T cells 
into IL-17–producing T cells but not sufficient to generate 
encephalitogenic T cells during primary stimulation, we spec-
ulated that an alternative pathway may occur in vivo that gen-
erates encephalitogenic Th17 cells. Because cytokines such as 
IL-1 and IL-23 had also been implicated in the differentia-
tion of Th17 cells and EAE (Langrish et al., 2005; Sutton 
et al., 2006), we investigated whether combinations of IL-6, 
TGF-, IL-1, and IL-23 might be required for the genera-
tion of encephalitogenic myelin-specific Th17 cells. Naive 
wild-type splenocytes, depleted of antigen presenting cells, 
were activated with plate-bound anti-CD3 + anti-CD28 with 
different combinations of these cytokines. As seen in Fig. 2 A, 
many combinations of these cytokines generated T cells capa-
ble of producing IL-17. However, in the absence of TGF-, 
IFN- was also produced, suggesting that TGF- may be 
critical for suppressing IFN- production, not necessarily in-
ducing IL-17 production. Because differentiation with IL-1 + 
IL-23 resulted in the greatest IL-17 production and IL-1 + 
IL-23 + TGF- had high IL-17 and low IFN-, we inves-
tigated whether these cytokine combinations may generate 
Th17 cells capable of inducing EAE. Splenocytes from naive 
TCR transgenic mice were differentiated in vitro with IL-6 + 
TGF-, IL-1 + IL-23, IL-1 + IL-23 + TGF-, or IL-12 
and transferred into B10.PL mice. The mice that received the 
T cells differentiated with IL-12 or IL-1 + IL-23 developed 
severe EAE (Fig. 2 B). As previously observed (Fig. 1 B), 
T cells differentiated with IL-6 + TGF- did not transfer 
disease. However, the mice that received the T cells differen-
tiated with IL-1 + IL-23 + TGF- did develop EAE (Fig. 2 B), 
albeit significantly milder cases than IL-12– or IL-1 + IL-
23–differentiated T cells. Analysis of the cytokines by flow 
cytometry at the time of transfer showed that T cells differen-
tiated with IL-1 + IL-23 + TGF- were both Th1 (9.24%) 
Figure 1.  Th17 cells differentiated in vitro with TGF- and IL-6 
do not transfer EAE. Naive V2.3/V8.2 transgenic splenocytes were 
differentiated in vitro with MBP Ac1-11 plus TGF- + IL-6 or IL-12 for 3 d. 
(A) Cells were harvested and analyzed by flow cytometry. Cells were gated 
on CD4+ T cells, and intracellular IL-17 and IFN- were analyzed. Data are 
representative of three independent experiments (percentages are shown). 
(B) Cells harvested from A were adoptively transferred into wild-type B10.
PL recipient mice. Data are representative of six independent experiments 
(means ± SEM). (C) Naive V2.3/V8.2 transgenic splenocytes were dif-
ferentiated in vitro with MBP Ac1-11 and TGF- + IL-6 for 3 d. The Th17 
cells were rested for 4 d and restimulated with MBP Ac1-11 in the ab-
sence of exogenous cytokines for 2 d. The cells were analyzed for intracel-
lular cytokines by flow cytometry (gated on CD4+ T cells; top) or 
transferred into naive B10.PL mice (Table I). CNS mononuclear cells were 
isolated from recipient B10.PL mice on day 7 after adoptive transfer (bot-
tom). Flow cytometry was used to evaluate IFN-– or IL-17–producing  
T cells. Cells were gated on CD45 and V8 TCR-positive cells. Data are 
representative of two independent experiments (percentages are shown).
the transferred T cells after secondary stimulation showed 
that there were actually three distinct populations of T cells 
generated during the restimulation: Th1 cells (37%), Th17 1552 T-BET DETERMINES T CELL ENCEPHALITOGENICITY | Yang et al.
cells differentiated with IL-12. As expected, the cells differen-
tiated with IL-6 + TGF- did not induce EAE; however, they 
did not reduce the severity of EAE in Th1-mediated disease 
when cotransferred into mice, indicating that they do not have 
a regulatory phenotype (Fig. S1).
Multiple cytokine combinations promote the differentiation 
of Th17 cells but fail to generate encephalitogenic Th17 cells
To determine to what extent IL-1, IL-6, IL-23, and TGF- 
contribute to the differentiation of Th17 cells and determine 
if any combination of these cytokines can generate encephali-
togenic Th17 cells, Th17 cells were generated using all com-
binations of these cytokines, or neutralizing these cytokines 
with antibodies. Because all combinations in the absence of 
TGF- could produce IFN- and TGF- had been impli-
cated as necessary for IL-17 production (Bettelli et al., 2006; 
Mangan et al., 2006; Veldhoen et al., 2006), all combinations 
included TGF- to increase the probability of generating pure 
Th17 cells. As seen in Table II and Fig. S2, the combination 
of all four cytokines generated the greatest number of IL-17–
producing T cells and relatively few IFN- T cells, but these 
cells, as well as all of the other combinations, failed to induce 
EAE when transferred into recipient mice. It is interesting to 
note that although IL-1 + IL-23 + TGF- generated mildly 
encephalitogenic T cells in Fig. 2, differentiation with IL-1 + 
IL-23 + TGF- + anti–IL-6 failed to generate encephalito-
genic T cells, suggesting that endogenous IL-6 was contribut-
ing to the development of encephalitogenic T cells. Analysis 
of T-bet by flow cytometry indicated that T-bet was decreased 
and Th17 (6.8%) cells, making it unclear whether the disease 
was mediated by IFN-– or IL-17–producing T cells (Fig. 2 C). 
We have shown previously that the IL-1R signaling pathway 
is critical for the production of IL-12 and the differentiation of 
encephalitogenic T cells (Deng et al., 2003), and thus it ap-
pears  that  IL-1  is  up-regulating  IL-12  in  antigen/APC-
driven differentiation, which subsequently favors Th1 cell dif-
ferentiation in the presence of IL-23. This experiment also 
illustrates  that  differentiation  with  anti-CD3  +  anti-CD28 
(Fig. 2 A) generates different T cell phenotypes than antigen/
APC-driven T cell differentiation (Fig. 2 C). Although this 
may be in part caused by cytokines produced by the APCs, it 
may also be caused by differences in signaling cascades medi-
ated by natural ligands that are not accurately recapitulated by 
antibody-mediated signaling (unpublished data).
It had also been suggested that in vivo–differentiated Th17 
cells  restimulated  with  IL-6  +  TGF-  induce  IL-10  and, 
therefore, these cells may be regulatory and not pathogenic 
(McGeachy et al., 2007). Therefore, IL-10 was analyzed by 
flow cytometry in these four differentiation conditions and did 
not correlate with encephalitogenicity (Fig. 2 C). In fact, dif-
ferentiation with IL-6 + TGF- generated the fewest IL-10–
producing T cells. Analysis of disease severity in all four groups 
indicated that severity correlated with the number of IFN-–
expressing CD4+ T cells and expression of T-bet, the tran-
scription factor that regulates IFN- expression (Table S1). To 
verify that IL-6 + TGF- was not promoting the differentia-
tion of regulatory T cells, TCR transgenic cells differentiated 
with IL-6 + TGF- were cotransferred with TCR transgenic 
Table I.  Th17 cells differentiated with IL-6 + TGF- are not encephalitogenic after primary stimulation
Cytokinesa
T cell differentiation IFN- IL-17 Incidence of EAE Mean day of onset Mean clinical score  
on day of onset
Primary stimulation
  Th17 (IL-6 + TGF-)  ++ 0/28 (0%) NA NA
  Th17 (IL-6 + TGF- + IL-23) + ++ 1/12 (8.3%) NA NA
  Th17 (IL-6 + TGF-) + PTXb  ++ 0/7 (0%) NA NA
  Th17 (IL-6 + TGF-) + Th1c  ++ 0/4 (0%) NA NA
  Th17 (IL-6 + IL-12/IFN-/IL-4)  + 17/17 (100%) 7.6 2.2
  Th17 (IL-6 + IL-12/IFN-/IL-4/TGF-)  + 4/5 (80%) 6.3 1.5
Secondary stimulationd
  Th17 (IL-6 + TGF-) +++ +++ 10/13 (76.9%) 6.2 2.8e
  Th17 (IL-6 + TGF- + IL-23) +++ +++ 6/7 (85.7%) 8 2.3
  Th17 (IL-6 + TGF- → IL-23)f +++ +++ 3/5 (60%) 11.3 1.3
  Th17 (IL-6 + TGF- → IL-1)f +++ +++ 4/5 (80%) 11 2.3
NA, not applicable.
aCytokine production was measured by ELISA at 72 h in culture during differentiation or following restimulation with MBP Ac1-11 only for secondary stimulation. +, <1 ng/ml; ++, 
1–4 ng/ml; +++, >4 ng/ml.
bMice were administered 200 ng pertussis toxin (PTX) on days 0 and 2 after transfer of Th17 (IL-6 + TGF-) cells into mice.
cMice were injected with 5 × 106 Th17 (IL-6 + TGF-) cells plus 106 Th1 (IL-12) cells.
dTh17 cells were rested for 4 d after differentiation and restimulated with MBP Ac1-11 only before transfer into naive B10.PL mice.
eThe rapid onset and severity of the disease required that the mice be euthanized within 48 h of disease onset, and therefore, only the mean clinical score at the time of 
disease onset could be determined.
f Th17 cells (IL-6 + TGF-) were rested for 4 d after differentiation and restimulated with MBP Ac1-11 + IL-23 or IL-1 before transfer into naive B10.PL mice.JEM VOL. 206, July 6, 2009 
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were cultured with MBP Ac1-11, MBP Ac1-11 + TGF-, 
or MBP Ac1-11 + IL-6 + TGF-. Flow cytometric analy-
sis demonstrated that T-bet levels were quite high (34%) in 
the splenocytes that received MBP Ac1-11 and inhibited in 
the splenocytes that had TGF- ± IL-6 (Fig. 3 A). Interest-
ingly, none of the stimulation conditions generated signifi-
cant amounts of IFN-, although IL-17 was detected in the 
presence of IL-6 + TGF- (Fig. 3 A). To determine if en-
cephalitogenicity in myelin-specific T cells from mice with 
spontaneous EAE is dependent on T-bet, the splenocytes 
were transfected with siRNA-Tbet or siRNA-nonsense (NS) 
before activation with MBP Ac1-11 (and nontransfected,   
>50% when IL-6 was neutralized (unpublished data). These 
data  suggest  that  in  vitro  conditions  that  include  TGF-, 
which are capable of producing CD4+ T cells that express 
high levels of IL-17, are probably not the same conditions that 
generate encephalitogenic Th17 cells in vivo.
Myelin-specific T cells in spontaneous EAE are dependent 
on T-bet for encephalitogenicity
To enhance our understanding of the characteristics of patho-
genic myelin-specific T cells, we phenotyped the myelin-
specific T cells in mice with spontaneous EAE. Splenocytes 
from TCR transgenic mice that developed spontaneous EAE 
Figure 2.  Encephalitogenicity correlates with IFN- production and T-bet expression. (A) Naive splenocytes from wild-type B10.PL mice were 
activated in vitro with anti-CD3/CD28 plus different combinations of cytokines for 72–96 h. ELISA was performed to detect IL-17 and IFN- secretion. 
Data are representative of three independent experiments (means ± SEM). (B) Naive V2.3/V8.2 transgenic splenocytes were differentiated in vitro with 
MBP Ac1-11 plus different combinations of cytokines for 3 d and transferred into naive B10.PL mice. Data are representative of two independent of ex-
periments (means ± SEM). (C) Cells from B were harvested and flow cytometry was used to evaluate IFN-, IL-17, IL-10, and T-bet (white, T-bet; gray, 
isotype control) expression in CD4+ T cells before transfer. Data are representative of two independent experiments (percentages are shown).1554 T-BET DETERMINES T CELL ENCEPHALITOGENICITY | Yang et al.
described in Table I, or anti-CD3/CD28. The cells were an-
alyzed by flow cytometry to determine the level of T-bet in 
the CD4+ T cells. The cells that produced IFN- or IL-17 
only had similar levels of T-bet, yet the cells that expressed 
both IFN- and IL-17 had significantly higher levels of 
T-bet (Fig. 3 C). Although the percentage of IL-17+ T cells was 
higher with anti-CD3/CD28 restimulation, IFN- expres-
sion was similar with antigen/APC or anti-CD3/CD28 re-
stimulation, indicating that the APCs were not responsible 
for the shift in cytokine production. In addition, the Th17 
cells differentiated with antigen/APCs were transfected with 
siRNA-Tbet or siRNA-NS after the rest and before restimu-
lation with MBP Ac1-11 and transferred into naive B10.PL 
mice. As expected, the mice that received the siRNA-NS–
transfected cells developed severe EAE, whereas the mice 
that received the siRNA-Tbet–transfected cells had a signifi-
cantly milder disease course (P = 0.002), suggesting that sup-
pressing T-bet was beneficial in ameliorating EAE mediated 
by Th1 and Th17 cells (Fig. 3 D). Flow cytometric analysis 
was used to verify efficient silencing of T-bet (Fig. 3 E) and 
analysis of cytokine production demonstrated that the amount 
of IL-17 was not altered by inhibiting T-bet, and IFN- was 
only modestly reduced (Fig. 3 F). These data indicate that al-
though cytokine expression was not significantly altered in 
the effector T cells by reduced T-bet expression, suppression 
of T-bet was able to ameliorate T cell effector function.
Encephalitogenic Th17 cells express T-bet
Because IFN-–deficient mice develop EAE and develop 
encephalitogenic Th17 and not Th1 cells, we examined 
whether the CNS-infiltrating T cells coexpressed IL-17 and 
T-bet. EAE was induced in B6/IFN-/ mice by immuni-
zation with MOG35-55/CFA and the mononuclear cells 
were isolated from the CNS during acute disease. The cells 
were incubated overnight with or without MOG35-55, and 
PMA/ionomycin was added to both cultures for the final 5 h. 
IL-17 was produced by the CD4+ T cells and expression was 
enhanced in the cells that received antigen (Fig. 4 A), indicat-
ing that the IL-17–producing T cells were specific for the 
immunizing antigen. Similarly, T-bet was expressed by the 
CNS-infiltrating CD4+ T cells, and T-bet expression was 
irradiated wild-type B10.PL splenocytes) and transferred 
into naive B10.PL mice. The majority of mice receiving the 
siRNA-NS–transfected cells developed EAE, whereas the 
mice receiving the siRNA-Tbet–transfected cells failed to 
develop disease (Table III). These data suggest that encepha-
litogenicity of myelin-specific effector T cells that arise in 
spontaneous EAE is dependent on T-bet for pathogenicity 
but not necessarily IFN-, which is a downstream product 
of T-bet transactivation.
Role of T-bet in IL-17 expression by myelin-specific T cells
We had previously demonstrated that inhibition of T-bet 
with siRNA in the adoptive transfer model of EAE prevents 
the development of Th17 cells in the CNS (Gocke et al., 
2007). However, we did not know if T-bet affected IL-17 
production in myelin-specific effector T cells. We had previ-
ously found that draining lymph nodes from B6 mice immu-
nized with MOG35-55/CFA express both Th1 and Th17 
cells, as well as a small population of T cells that express both 
IFN- and IL-17 (unpublished data). To determine if T-bet 
plays a role in IL-17 production in T cells generated in vivo, 
B6 mice were immunized with MOG35-55/CFA and ad-
ministered siRNA-Tbet or siRNA-NS via the tail vein to 
determine if T-bet affected the phenotype of the myelin-spe-
cific T cells that differentiated in vivo. The draining lymph 
nodes were removed 12 d later and stimulated with MOG35-55. 
Flow cytometric analysis demonstrated that the number of 
IFN-–expressing cells was reduced by 65% and that there 
were no detectable IL-17–producing T cells from the mice 
treated with siRNA-Tbet (Fig. 3 B). These data indicate that 
inhibition of T-bet suppresses the differentiation and/or ex-
pansion of both Th1 and Th17 cells.
Because myelin-specific TCR transgenic T cells differen-
tiated with IL-6 + TGF- do not transfer EAE (Fig. 1 B), but 
restimulation of these cells with antigen only generates highly 
encephalitogenic  T  cells  composed  of  three  populations, 
IFN-+, IL-17+, and IFN-/IL-17 double-positive T cells 
(Fig. 1 C), we determined the expression of T-bet in these 
three T cell populations. Naive myelin-specific TCR trans-
genic T cells were differentiated with MBP Ac1-11 + IL-6 + 
TGF-, rested, and restimulated with MBP Ac1-11 only, as 
Table II.  Th17 cells generated in vitro with TGF- fail to induce EAE
Differentiation conditions IFN-a IL-17a IL-10a EAE incidence
TGF- + IL-1 + IL-23 + IL-6 2.1 24 4.8 0/5
TGF- + IL-1 + IL-23 + IL-6 4.8 1.5 1.3 0/5
TGF- + IL-1 + IL-23 + IL-6 2.5 17 3 0/5
TGF- + IL-1 + IL-23 + IL-6 1.5 12 2.3 0/6
TGF- + IL-1 + IL-23 + IL-6 1.7 16 1.7 0/6
TGF- + IL-1 + IL-23 + IL-6 3.7 0.9 1.2 0/5
TGF- + IL-1 + IL-23 + IL-6 6.6 1.6 1.6 0/5
Bolded terms indicate antibodies to a specific cytokine.
aThe percentage of cytokine-positive CD4+ T cells as determined by intracellular flow cytometric analysis. ELISA was used to measure cytokine production and correlated with 
the percentage of cytokine-positive CD4+ T cells.JEM VOL. 206, July 6, 2009 
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Figure 3.  T-bet expression correlates with encephalitogenicity. (A) Splenocytes from a V2.3/V8.2 transgenic mouse with spontaneous EAE were 
activated in vitro with MBP Ac1-11, MBP Ac1-11 plus TGF-, or MBP Ac1-11 plus TGF-/IL-6 for 3 d. Flow cytometry was used to evaluate cytokine produc-
tion and T-bet expression on CD4+ T cells. Data are representative of two independent experiments (percentages are shown). (B) B6 wild-type mice were in-
jected with siRNA-Tbet or siRNA-NS at the time of immunization with MOG35-55/CFA. The lymph nodes were removed on day 11 after immunization and 
stimulated with MOG 35–55 for 3 d. Flow cytometry was used to evaluate cytokine production on activated CD4+ T cells and to confirm T-bet suppression 
that was >95% (not depicted). Data are representative of two independent experiments (percentages are shown). (C) Naive V2.3/V8.2 transgenic spleno-
cytes were differentiated into Th17 cells in vitro with MBP Ac1-11 plus TGF-/IL-6 for 3 d. Cells were rested and restimulated with MBP Ac1-11 in the pres-
ence of irradiated feeders or with1 µg/ml each of plate-bound anti-CD3/CD28. After 48 h, cells were analyzed by flow cytometry. Cells were gated on CD4 and 
T-bet expression was analyzed in each quadrant based on IL-17 and IFN- expression (gray, isotype control; white, T-bet). Data are representative of two in-
dependent experiments (percentages are shown). (D) Naive V2.3/V8.2 transgenic splenocytes were differentiated into Th17 cells in vitro with MBP Ac1-11 
plus TGF-/IL-6 for 3 d. Cells were rested for 4 d and transfected with siRNA-Tbet or siRNA-NS, followed by a 2-d restimulation with MBP Ac1-11 with non-
transfected irradiated feeder cells. 5 × 106 cells per mouse were transferred into naive B10.PL mice. Data are representative of three independent experiments 
(means ± SEM). (E) T-bet suppression was verified by flow cytometry. Data are representative of two independent experiments (percentages are shown).  
(F) ELISA was performed to detect IL-17 and IFN- secretion of the cells before transfer. Data are representative of two independent experiments (means ± SEM).
higher in the MOG35-55–stimulated cells (Fig. 4 B). Analy-
sis of T-bet in the CD4+IL-17+ T cells demonstrated that   
T-bet expression was almost threefold higher in the antigen-
stimulated cells compared with the cells stimulated without an-
tigen (Fig. 4 C, right), illustrating that T-bet was expressed by 
the MOG35-55–specific Th17 cells in the CNS. Interestingly, 1556 T-BET DETERMINES T CELL ENCEPHALITOGENICITY | Yang et al.
and IFN- expression was analyzed. Although IFN- was 
observed under all cytokine conditions and is also seen with 
antigen-only differentiation, IL-17 was only observed with 
IL-6 differentiation (Fig. 6 A). Therefore, we compared IL-17 
production by ELISA when the TCR transgenic cells were 
differentiated with IL-6 versus IL-6 + TGF- and found that 
the amount of IL-17 was similar under both conditions   
(Fig. 6 B). To generate pure populations of Th17 cells that ex-
press T-bet, TCR transgenic splenocytes were differentiated 
with IL-6 ± TGF- in the presence of neutralizing antibodies 
to IFN-, IL-12, and IL-4. Differentiation with IL-6 in the 
absence of IFN-, IL-12, and IL-4 generated IL-17+ IFN-- 
T cells that expressed T-bet (Fig. 6 C). IL-17 production was 
confirmed by ELISA (Fig. 6 D). The Th17 cells generated 
with IL-6 induced disease similar to Th1 cells (Fig. 6 E), sug-
gesting that IL-6, in the absence of exogenous TGF-, pro-
motes the differentiation of encephalitogenic Th17 cells.
Because the amount of IL-17 was reduced in the absence 
of exogenous TGF- and bovine serum may contain TGF- 
that may contribute to the differentiation of Th17 cells with 
IL-6, the experiment was repeated with a neutralizing anti-
body to TGF- included during the T cell differentiation. 
Using threefold higher amounts of anti–TGF- than recom-
mended by the manufacturer, we found that T-bet levels in 
the total CD4+ population were higher in the T cells differ-
entiated with IL-6 + anti–IL-12/IFN-/IL-4 with anti–TGF- 
than T-bet levels in the T cells differentiated with IL-6 + 
anti–IL-12/IFN-/IL-4 only (Fig. 7 A, top). However, the 
amount of IL-17 expressed by CD4+ T cells was very low by 
intracellular cytokine staining and decreased by 50% by ELISA 
in the presence of anti–TGF- compared with IL-6 + anti–
IL-12/IFN-/IL-4 only (Fig. 7 A, middle; and Fig. 7 B), in-
dicating that TGF- was contributing to the amount of IL-17 
produced. Transfer of TCR transgenic T cells differentiated 
with IL-6 + TGF-, IL-6 + anti–IL-12/IFN-/IL-4, and 
IL-6 + anti–IL-12/IFN-/IL-4/TGF- demonstrates that 
omitting or neutralizing TGF-–generated encephalitogenic 
T cells (Fig. 7 C). Neutralization of all active TGF- in the 
cultures was confirmed by ELISA (unpublished data). Analysis 
of T-bet expression in the IFN-+ and IL-17+ T cells demon-
strates that T-bet is present in encephalitogenic T cell popula-
tions (Fig. 7 A, bottom). However, the low numbers of 
IL-17+ T cells in IL-6 + anti–IL-12/IFN-/IL-4/TGF- dif-
ferentiation precluded analysis of this population. There was 
no IFN- production, as measured by ELISA, by T cells dif-
ferentiated with IL-6 under any condition in Fig. 7 (C and D) 
(not depicted). The amount of IL-17 produced, as measured 
by ELISA, in the presence of IL-6 clearly correlated with the 
there was no T-bet expression in the IL-17 cells (Fig. 4 C, 
left), indicating that CD4+ T cells were not differentiating 
toward an IFN- Th1 phenotype. To determine if T-bet 
was also expressed in IL-17+ T cells in the CNS in adoptive 
transfer EAE, TCR transgenic cells were differentiated into 
Th17 cells with IL-6 + TGF-, rested, restimulated with an-
tigen and transferred into naive mice. Similar to previous ex-
periments (Fig. 1 C), IL-17+, IFN-+, and double-positive   
T cells were found in the CNS cells. T-bet was observed in 
the CD4+IL-17+ and CD4+IFN-+ T cells, indicating that 
T-bet was expressed in the IL-17+– and IFN-+–infiltrating 
T cells (Fig. 4 D). The number of CD4+IL-17+IFN-+ T cells 
was too low to accurately determine T-bet expression in 
this population.
Because T-bet–deficient mice do not develop EAE, yet 
IFN-/ mice are EAE susceptible, we compared the Th17 
cells in these two strains of mice. B6, B6/IFN-/, and B6/
T-bet/ mice were immunized with MOG35-55 and the 
draining lymph nodes were removed on day 12. Because 
CNS-infiltrating cells could not be analyzed because T-bet/ 
mice do not develop EAE, flow cytometric analysis was per-
formed on the lymph node cells. Both IFN-/ and T-bet/ 
mice had significantly more activated MOG35-55–specific 
Th17 cells than the B6 control mice (Fig. 5 A). T-bet expres-
sion was higher in the CD4+ T cells from IFN-/ mice 
compared with B6 mice and absent in T-bet/ mice (Fig. 5 B), 
which correlates with the observation that IFN-–deficient 
mice develop more severe EAE than wild-type mice. In ad-
dition, T-bet was expressed in the activated CD4+ Th17 cells 
(Fig. 5 C), illustrating that T-bet is expressed by Th17 cells 
differentiated in vivo that cause EAE. The fact that the drain-
ing  lymph  node  cells  from  T-bet/  mice  (EAE-resistant 
mice) express similar levels of IL-17 in the absence of T-bet 
as IFN-/ mice (EAE-susceptible mice) indicates that T-bet 
is a critical factor for determining the encephalitogenicity of 
Th17 cells. In addition, the cells were transferred into wild-type 
B6 mice, and EAE was induced by the B6 and B6/IFN-/ 
MOG35-55 T cells but not the B6/T-bet/ cells (Fig. 5 D), 
confirming the encephalitogenicity of the T-bet+ IL-17+ T cells 
but not the T-bet IL-17+ T cells.
IL-6 promotes the differentiation of encephalitogenic  
Th17 cells
To determine the cytokines that promote the differentiation 
of T-bet+ IL-17+ T cells, we analyzed T-bet expression by 
flow cytometry in TCR transgenic splenocytes differentiated 
with antigen/APCs and IL-6, IL-1, and/or IL-23 in the ab-
sence of TGF-. CD4+ T-bet+ T cells were gated, and IL-17 
Table III.  Encephalitogenicity in spontaneous EAE is dependent on T-bet
Incidence of EAE Mean day of onseta Maximum clinical score Peak mean clinical scorea
siRNA-NS 5/8 (62.5%) 10.8 ± 1.1 2 1.1 ± 1
siRNA-Tbet 0/8 (0%) NA NA NA
NA, not applicable.
aMean day of onset and peak mean clinical score were determined for the five mice that developed EAE.JEM VOL. 206, July 6, 2009 
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express low IL-17, no IFN-, and high T-bet is quite similar 
to our observation in spontaneous EAE in TCR transgenic 
mice in which T-bet levels are high yet cytokine production 
is undetectable (Fig. 3 A and Table III), supporting a critical 
amount of TGF- present (Fig. 7 B), and encephalitogenicity 
correlated with T-bet expression (Fig. 7, A and C). The ob-
servation that differentiation with IL-6 + anti–IL-12/IFN-/
IL-4/TGF- generates encephalitogenic CD4+ T cells that 
Figure 4.  Myelin-specific T cells in the CNS of IFN-–deficient mice express IL-17 and T-bet. EAE was induced in B6/IFN-/ mice by immu-
nization with MOG35-55 emulsified in CFA. The CNS-infiltrating mononuclear cells were isolated from the brains and spinal cords of 14 mice 5 d after the 
mice began to develop signs of EAE. The cells were cultured overnight with or without 2 µg/ml MOG35-55. PMA/ionomycin was added to all cells during 
the last 5 h of culture. Cells were gated on CD45 and CD4. (A) Intracellular IL-17 expression. (B) Intracellular T-bet expression (white, T-bet; gray, isotype 
control). (C) T-bet expression was analyzed in the CD4+IL-17+ and CD4+IL-17 T cells in the absence or presence of MOG35-55 (white, T-bet; gray, isotype 
control). (D) Naive TCR transgenic splenocytes were differentiated with IL-6 + TGF-, rested, restimulated with antigen, and transferred into naive B10.PL 
mice. Inflammatory cells were isolated in the CNS and gated on CD45 and CD4, and T-bet expression in the IL-17+ and IFN-+ T cells was determined 
(white, T-bet; gray, isotype control). Data in A–D are representative of two independent experiments (percentages are shown).1558 T-BET DETERMINES T CELL ENCEPHALITOGENICITY | Yang et al.
ients (Langrish et al., 2005; McGeachy et al., 2007; Stromnes   
et al., 2008). However, these studies never excluded the possi-
bility that myelin-specific Th1 cells were also being transferred, 
and two studies actually show that IFN- is produced by the 
transferred  populations  (McGeachy  et  al.,  2007;  Stromnes   
et al., 2008). In addition, several studies had identified condi-
tions that promoted the differentiation of Th17 cells (Bettelli 
et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006) yet 
had not determined if these differentiation conditions actually 
yielded encephalitogenic T cells. Using myelin-specific TCR 
transgenic mice that are housed in a specific pathogen-free en-
vironment, T cells were differentiated with TGF- and com-
binations of IL-1, IL-6, and IL-23. Although several cytokine 
combinations generated myelin-specific T cells that expressed 
role for T-bet in encephalitogenic T cells regardless of IFN- 
and IL-17 expression. Ex vivo analysis of these encephalito-
genic IL-6–differentiated T cells found that the majority of 
CNS-infiltrating CD4+ T cells expressed neither IFN- or 
IL-17  (94%),  but  there  was  a  small  population  expressing 
IFN- (5.2%), indicating that reexposure to antigen in vivo 
may influence cytokine expression (Fig. 7 D).
DISCUSSION
This study was initiated to determine the role of myelin-spe-
cific Th17 cells in EAE pathogenesis. Previous EAE studies had 
demonstrated that Th17 cells generated in vivo by immuniza-
tion with myelin peptides in CFA could be expanded in vitro 
with IL-23 and induce EAE when transferred into naive recip-
Figure 5.  IFN-/ and T-bet/ mice generate myelin-specific Th17 cells, although EAE susceptibility differs. B6, B6/IFN-/, and B6/T-bet/ 
mice were immunized with MOG35-55 emulsified in CFA. The draining lymph nodes of three mice per group were removed on day 12 and cultured with 
MOG35-55 for 3 d. (A) Cells were gated on CD4 and IL-17 expression was analyzed in the activated (CD44hi) T cells (percentages are shown). (B) T-bet expres-
sion in the CD4+ T cells was analyzed (white, T-bet; gray, isotype control; percentages are shown). (C) The percentage of T-bet+ cells was determined by gating 
on the CD4+IL-17+ T cells. (D) Splenocytes from B6, B6/IFN-/, and B6/T-bet/ mice immunized with MOG35-55 were stimulated in vitro with MOG35-55 
and transferred into wild-type B6 mice and monitored for EAE development. Data are representative of two independent experiments (means ± SEM).JEM VOL. 206, July 6, 2009 
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Figure 6.  IL-6, in the absence of exogenous TGF-, promotes the differentiation of encephalitogenic Th17 cells. (A) Naive TCR transgenic 
splenocytes were differentiated with MBPAc1-11 and IL-6, IL-1, IL-23, or IL-1 + IL-23. Cells were gated on CD4+ T cells and T-bet expression was ana-
lyzed. IFN- and IL-17 expression on CD4+ T-bet+ cells was then analyzed (percentages are shown). (B) Naive TCR transgenic splenocytes were differenti-
ated with IL-6, TGF-, or both and cytokine production was determined by ELISA from the supernatants (means ± SEM). (C) Naive TCR transgenic 
splenocytes were differentiated with IL-12 or IL-6 (±TGF-) in the presence of neutralizing antibodies for IFN-, IL-12, and IL-4. Flow cytometry ana-
lyzed IL-17, IFN-, and T-bet expression in these cells (percentages are shown). (D) ELISA was used to measure cytokine expression from supernatants of 
cells in C (means ± SEM). (E) The cells in D were transferred into naive B10.PL mice (5 × 106 cells per mouse) and monitored for development of EAE. 
Data are representative of three independent experiments (means ± SEM).
high levels of IL-17 in the absence of IFN-, these Th17 cells 
failed to induce EAE. As others have shown (Langrish et al., 
2005), we found that in vivo–differentiated Th17 cells that 
are expanded in vitro with IL-23 are highly encephalitogenic 
(unpublished data), suggesting that myelin-specific Th17 cells 
contribute to disease pathogenesis. Thus, it appears that an al-
ternative differentiation pathway generates encephalitogenic 
autoreactive Th17 cells in vivo.1560 T-BET DETERMINES T CELL ENCEPHALITOGENICITY | Yang et al.
Figure 7.  TGF- contributes to IL-17 expression but not the encephalitogenic capacity of T cells differentiated with IL-6. Naive TCR 
transgenic splenocytes were differentiated with IL-12 (Th1), IL-6 + TGF- + anti–IL-12/IFN-/IL-4, IL-6 + anti–IL-12/IFN-/IL-4, or IL-6 + anti–IL-12/
IFN-/IL-4/TGF-. (A) T-bet (white histogram; gray, isotype control) expression in total CD4+ T cells was determined by flow cytometry (top). IL-17 and 
IFN- expression in CD4+ T cells was determined (middle). IFN- and IL-17 were gated on and T-bet levels were determined in each population.  
Because the number of IL-17+ T cells was low with IL-6 + anti–IL-12/IFN-/IL-4/TGF- differentiation, T-bet levels could not accurately be determined. 
(B) IL-17 levels from the supernatants from A were determined by ELISA. IFN- levels were undetectable in all IL-6 cultures (not depicted; means ± 
SEM). (C) The T cell populations differentiated with IL-6 were transferred in to B10.PL (5 × 106 cells per mouse) and monitored for EAE development 
(means ± SEM). (D) The CNS-infiltrating cells were isolated from the mice receiving the IL-6-differentiated (neutralizing other cytokines) T cells on day 
12 after transfer. The cells were stimulated in vitro overnight with MBPAc1-11, and intracellular IFN- and IL-17 were analyzed by flow cytometry. 
Data in A–D are representative of two independent experiments.
Because myelin-specific Th17 cells differentiated in vitro 
with IL-6 + TGF- were not pathogenic after primary dif-
ferentiation, we speculated that they may be inefficient effec-
tor T cells until reexposure to antigen. However, restimulation 
of Th17 cells generated in vitro resulted in decreased IL-17 
production and increased IFN- production, suggesting that 
Th17 cells may not have a stable phenotype. In addition, 
these cells transferred disease, but it was not clear whether JEM VOL. 206, July 6, 2009 
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taneous EAE, T-bet expression was high, although these cells 
produced little, if any, IFN- or IL-17, suggesting that T-bet 
may be regulating other genes or pathways that are critical for 
encephalitogenicity, which may be unrelated to cytokine pro-
duction. We have previously shown that suppression of T-bet 
inhibits IL-23R expression, and that T-bet binds the IL-23R 
promoter and plays a direct role in the transactivation of the 
IL-23R gene (Gocke et al., 2007). Historically, IL-23R was 
identified as a marker of memory Th1 cells (Oppmann et al., 
2000; Parham et al., 2002), although the more recent literature 
suggests that the IL-23R pathway is critical for IL-17 produc-
tion (Aggarwal et al., 2003; Langrish et al., 2005; Stromnes   
et al., 2008). These data were ascertained by studying mRNA 
or how T cells responded to IL-23. Unfortunately, there is no 
commercial IL-23R antibody available for flow cytometric 
analysis to definitively determine the cell populations that ex-
press this receptor and how the engagement of the IL-23R af-
fects cytokine production and pathogenicity by Th1 or Th17 
cells. However, it is clear that IL-23–deficient mice do not 
develop EAE, and thus, IL-23R engagement is critical in the 
pathogenesis of the disease (Cua et al., 2003). Therefore, it is 
possible that T-bet up-regulates IL-23R expression and that 
engagement of the IL-23R, whether on Th1 or Th17 cells, 
generates highly encephalitogenic CD4+ T cells. However, 
other genes such as osteopontin have also been shown to be 
regulated by T-bet, and osteopontin-deficient mice have a re-
duced susceptibility to EAE (Chabas et al., 2001; Jansson et al., 
2002; Shinohara et al., 2005), necessitating a comprehensive 
analysis of genes transactivated by T-bet and their contribution 
to T cell encephalitogenicity.
The critical role of T-bet for encephalitogenicity was ob-
served when siRNA was used to silence T-bet in highly en-
cephalitogenic T cells that express both IFN- and IL-17, 
resulting in the reduced pathogenic potential of these myelin-
specific T cells. In addition, administration of T-bet siRNA to 
mice immunized with myelin peptides in CFA reduces both 
IFN- and IL-17 production, suggesting that T-bet’s role in 
T cell differentiation is not limited to Th1 cells. We con-
firmed this observation by analyzing myelin-specific T cells 
from the CNS of IFN-/ mice that express both IL-17 and 
T-bet. In IL-23–driven IL-17–producing T cells from my-
elin-immunized mice, T-bet was also observed in these patho-
genic IL-17–producing T cells (Chen et al., 2006). Analysis of 
the draining lymph nodes after active induction of EAE dem-
onstrated that the Th17 cells in IFN-/ mice express higher 
levels of T-bet than wild-type controls, which suggest that 
encephalitogenicity is associated with enhanced T-bet expres-
sion. The fact that the draining lymph node cells from T-bet/ 
mice express similar levels of Th17 cells in the absence of 
T-bet as IFN-/ mice indicates that T-bet is a critical factor 
for determining encephalitogenicity, not IL-17 expression. It 
is also interesting to note that systemic administration of T-bet 
siRNA in wild-type mice suppresses development of Th17 
cells, whereas immunization of mice with a genetic deletion 
of T-bet results in a significant population of nonencephalito-
genic Th17 cells. This suggests that mice incapable of generating 
the disease was caused by IFN-–, IL-17–, or IFN-/IL-17–
producing T cells because all were present in the transferred 
cells. Because identification of IFN-– and IL-17–producing 
cells requires intracellular cytokine staining, it is not possible 
to sort these cells and transfer each population into recipient 
mice to identify the pathogenic T cell population. However, 
we were able to isolate the T cells from the CNS of these 
mice after disease onset and found that the majority of the 
myelin-specific T cells in the CNS produced IFN-.
Because production of IL-17 was not sufficient for enceph-
alitogenicity in our study but IFN- was consistently associ-
ated with disease, we analyzed other factors that may determine 
whether a myelin-specific CD4+ T cell population was en-
cephalitogenic. One study suggested that IL-6 + TGF- may 
not generate pathogenic Th17 cells, because myelin-specific   
T cells restimulated with these cytokines expressed IL-10   
(McGeachy et al., 2007). In that study, myelin-specific T cells 
from immunized mice were restimulated in vitro with IL-6 + 
TGF- ± IL-23 and analyzed for cytokine expression by flow 
cytometry, and it was found that the cells failed to transfer 
disease. However, cotransfer of these IL-10–producing cells 
with encephalitogenic T cells protected mice from EAE, sug-
gesting that the cells were regulatory. In our study, we found no 
association between IL-10 production and encephalitogenicity 
in T cells undergoing primary differentiation with IL-6 + 
TGF-. In fact, IL-10 expression was lowest in the T cells dif-
ferentiated with IL-6 + TGF-. Cotransfer of Th1 cells with 
Th17 cells differentiated with IL-6 + TGF- did not protect 
mice from EAE (Fig. S1). In contrast, T-bet expression had the 
highest correlation with encephalitogenicity. Thus, we speculate 
that TGF-, a known antagonist of T-bet expression (Gorelik 
et al., 2002; Park et al., 2005), may be responsible for minimiz-
ing the encephalitogenic capacity of myelin-specific Th17 cells 
generated in vitro with IL-6 + TGF-.
T-bet is a transcription factor that was first associated with 
the  differentiation  of  Th1  cells  and  IFN-  production  by 
CD4+ T cells (Szabo et al., 2000). We and others have found 
that T-bet is essential for the development of EAE (Bettelli   
et al., 2004; Lovett-Racke et al., 2004; Nath et al., 2006; 
Gocke et al., 2007) even though T-bet–deficient mice pro-
duce IL-17 (Harrington et al., 2005; Furuta et al., 2008; Phoon 
et al., 2008). In fact, several models of autoimmunity in which 
IL-17 has been implicated as a pathogenic cytokine are not in-
ducible in T-bet–deficient mice (Neurath et al., 2002; Peng 
et al., 2002; Bettelli et al., 2004; Juedes et al., 2004; Nath et al., 
2006; Wang et al., 2006). These observations suggest that the 
generation of autoreactive Th17 cells in the absence of T-bet 
is not sufficient to induce autoimmunity, even when the Th17 
cells are differentiated in vivo. Myelin-specific T cells from 
T-bet–deficient mice fail to transfer disease to wild-type mice, 
confirming that T-bet is necessary for the generation of en-
cephalitogenic T cells (Nath et al., 2006). Encephalitogenic 
T cells differentiated in vitro with IL-12 or IL-1 + IL-23 
expressed high levels of T-bet, whereas addition of TGF- 
consistently reduced T-bet expression and encephalitogenic 
capacity. When T-bet levels were analyzed in mice with spon-1562 T-BET DETERMINES T CELL ENCEPHALITOGENICITY | Yang et al.
IL-6, 10 ng/ml IL-23, 1 ng/ml TGF-, 4.5 µg/ml anti–IL-1, 2 µg/ml 
anti–IL-6, 5 µg/ml anti–IL-23, 2 µg/ml anti–IFN-, 1 µg/ml anti–IL-12, 
2 µg/ml anti–IL-4, and 0.35 µg/ml anti–TGF-. After 72 h, the cells were 
washed with PBS and 5 × 106 cells were injected i.p. into naive B10.PL 
mice. The mice were evaluated daily for clinical signs of EAE, as described 
in the previous paragraph.
Administration of siRNA in vivo and transfection with siRNA in 
vitro. Synthetic siRNA was purchased from Thermo Fisher Scientific, and 
stocks were prepared in the RNase-free H2O at 160 µM and diluted to 
50 µg/100 µl PBS (2 mg/kg/mouse) for i.v. administration via the tail vein. 
For in vitro transfection of Th17 cells, splenocytes from naive V2.3/V8.2 
TCR transgenic mice were cultured with 2 µg/ml of MBP Ac1-11 and 
TGF- + IL-6 for 3 d to differentiate Th17 cells. The cells were rested for   
4 d and transfected with siRNA-Tbet or siRNA-NS, as described previously 
(Lovett-Racke et al., 2004). After overnight transfection, the cells were 
washed and stimulated with 2 µg/ml of peptide in the presence of wild-type, 
nontransfected, irradiated splenocytes at a ratio of 1:5. For in vitro transfec-
tion of splenocytes from TCR transgenic mice with spontaneous EAE, the 
cells were transfected with siRNA overnight as previously described (Bettelli 
et al., 2006), washed, and activated with 2 µg/ml of MBP Ac1-11 in the pres-
ence of wild-type, nontransfected, irradiated splenocytes at a ratio of 1:5.
Cytokine ELISA. Supernatants were collected from TCR transgenic sple-
nocytes cultured at 2 × 106 cells/well with irradiated wild-type splenocytes 
(6 × 106 cells/well) in 24-well plates. Purified anti–mouse primary antibodies 
(BD) were diluted in 0.1 M NaHCO3 (pH 8.2) at 2 µg/ml. Immunolon II 
plates (Dynatech Laboratories) were coated with 50 µl of primary antibodies 
per well and incubated overnight at 4°C. The plates were washed twice with 
PBS/0.05% Tween 20. The plates were blocked with 200 µl of 1% BSA in 
PBS per well for 2 h. The plates were washed twice with PBS/Tween 20, and 
100 µl of supernatants were added in duplicate. The plates were incubated over-
night at 4°C and washed four times with PBS/Tween 20. Biotinylated rat anti–
mouse secondary antibodies (BD) were diluted in PBS/1% BSA, 100 µl of 
1-µg/ml biotinylated antibodies was added to each well, and plates were incu-
bated at room temperature for 1 h. The plates were washed six times with PBS/
Tween 20, and 100 µl avidin-peroxidase was added at 2.5 µg/ml and incubated 
for 30 min. The plates were washed eight times with PBS/Tween 20, and   
100 µl ABTS substrate containing 0.03% H2O2 was added to each well. The 
plate was monitored for 10–20 min for color development and read at A405. 
A standard curve was generated from the IFN-, IL-10, and IL-17 standards, and 
the concentration of IFN-, IL-10, and IL-17 in the samples was calculated.
Intracellular staining and flow cytometry. Flow cytometric analysis was 
performed to evaluate cytokine production and T-bet expression in spleno-
cytes and CNS-infiltrating cells. CNS-infiltrating cells were prepared as previ-
ously described (Gocke et al., 2007). Splenocytes and/or CNS mononuclear 
cells were cultured with or without antigen. For the last 4–5 h of the incuba-
tion, 50 ng/ml PMA and 750 ng/ml ionomycin were added to cells. 1 µl/ml 
GolgiPlug was added to each well to block cytokine secretion 4 h before stain-
ing. Cells were collected, washed, and incubated with Fc block (BD) on ice 
for 15–20 min. The cells were washed and resuspended in staining buffer (1% 
BSA in PBS). The cells were incubated with mAbs to the cell-surface markers 
for 30 min at 4°C. After washing twice with staining buffer, cells were fixed 
and permeabilized using Cytofix/Cytoperm solution (BD) for 20 min at 4°C. 
Cells were stained for intracellular cytokines and T-bet with mAb diluted in 
PermWash solution for 30 min at 4°C. 80,000–100,000 live cell events were 
acquired on a FACSCalibur or FACSCanto (BD) and analyzed using FlowJo 
software (Tree Star, Inc.). PerCP-conjugated anti-CD45, allophycocyanin 
(APC)-conjugated  anti-V2,  FITC-conjugated  anti-V8,  PE-conjugated 
anti–IL-17, APC-conjugated anti–IFN-, PerCP-conjugated anti-CD4, and 
APC-conjugated  anti–IL-10  were  purchased  from  BD.  FITC-conjugated 
anti–T-bet was purchased from Santa Cruz Biotechnology, Inc.
Statistical analysis. A statistically significant difference in EAE clinical scores 
was considered to be P < 0.05 as determined by Mann-Whitney U test. 
Th1 (T-bet/ and IFN-/ mice) promote Th17 cell dif-
ferentiation but that wild-type mice in which T-bet is sup-
pressed via siRNA do not favor Th17 cell differentiation, pos-
sibly because of Th1-related cytokines that are still present at 
low levels in the environment.
It was still unclear how T-bet+ IL-17+ encephalitogenic 
T cells could be generated if TGF- was critical for development 
of Th17 cells. However, IL-6, in the absence of exogenous 
TGF- and Th1-associated cytokines, promoted the differen-
tiation of encephalitogenic Th17 cells that expressed T-bet. 
This confirmed that myelin-specific Th17 cells can induce 
EAE, but that T-bet must be expressed either by differentia-
tion in a TGF-–low environment or differentiation with   
IL-6 + TGF- and reexposure to antigen in a TGF-–low 
environment to allow for up-regulation of T-bet. The data in 
this study clearly define the necessity of T-bet in the develop-
ment of autoimmune demyelinating disease, but they do not 
exclude the possibility that T-bet T cells contribute to patho-
genesis. In addition, T-bet may be contributing to disease in 
multiple cell types, such as dendritic cells as observed in in-
flammatory arthritis (Wang et al., 2006), although this study 
focuses specifically on the role of T-bet in CD4+ T cells.
Although this study was initially designed to determine the 
role of myelin-specific Th1 and Th17 cells in EAE pathogen-
esis, we have found that pathogenesis is more closely associ-
ated with a transcription factor than cytokine production. We 
typically associate CD4+ T cell function with the cytokines 
that they produce. However, both IFN-– and IL-17–defi-
cient mice develop EAE, although the disease course is altered 
(Ferber et al., 1996; Komiyama et al., 2006; Haak et al., 2009). 
In the case of autoimmunity, the function of autoreactive 
T cells may be mediated by a particular signaling pathway 
(i.e., T-bet) that programs the cells to be pathogenic, and not 
the end product of a pathway (i.e., cytokine production).
MATERIALS AND METHODS
Induction of EAE. B10.PL mice transgenic for the MBP Ac1-11–specific 
TCR chains V2.3 or V8.2 were a gift from J. Goverman (University of 
Washington, Seattle, WA; Goverman et al., 1993). B10.PL, B6, B6/IFN-/, 
and B6/T-bet/ mice were purchased from the Jackson Laboratory and bred 
in a specific pathogen-free animal facility at Ohio State University (OSU) 
Medical Center. All animal protocols were approved by the OSU Institu-
tional Animal Care and Use Committee. EAE was induced in 8–10-wk-old 
B10.PL or B6 mice by s.c. injection over four sites in the flank with 200 µg 
MBP Ac1-11 or MOG35-55, respectively (Invitrogen) in an emulsion with 
CFA (Difco). 200 ng pertussis toxin per mouse in PBS was injected i.p. at the 
time of immunization and 48 h later. Mice were scored on scale of 0 to 6: 
0, no clinical disease; 1, limp/flaccid tail; 2, moderate hind limb weakness; 3, 
severe hind limb weakness; 4, complete hind limb paralysis; 5 quadriplegia or 
premoribund state; and 6, death.
EAE was also induced by adoptive transfer. Spleens from naive 5–10-
wk-old V2.3/V8.2 TCR transgenic mice were removed and single-cell 
suspensions were prepared. The naive status of the TCR transgenic T cells 
was verified by analysis of CD62 and CD44 by flow cytometry. Splenocytes 
were cultured in 24-well plates at 2 × 106 cells/well with irradiated B10.PL 
splenocytes (6 × 106 cells/well). Cells were activated with 2 µg/ml of MBP 
Ac1-11 and different combination of cytokines or neutralizing antibodies 
for cytokines to differentiate Th1 or Th17 cells. Cytokine and antibody 
concentrations were as follows: 0.5 ng/ml IL-12, 10 ng/ml IL-1, 25 ng/ml   JEM VOL. 206, July 6, 2009 
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